Difference between revisions of "Gestational trophoblastic neoplasia"
Jump to navigation
Jump to search
(correction in dactinomycin frequency) |
m |
||
| Line 22: | Line 22: | ||
![[Levels_of_Evidence#Efficacy|Efficacy]] | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG)] | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] |
| − | |style="background-color:#1a9851"|Phase III | + | |style="background-color:#1a9851"|Phase III (E) |
|[[#Methotrexate_monotherapy|Methotrexate]] | |[[#Methotrexate_monotherapy|Methotrexate]] | ||
|style="background-color:#91cf60"|Seems to have superior CR rate | |style="background-color:#91cf60"|Seems to have superior CR rate | ||
| Line 33: | Line 33: | ||
'''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | '''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | ||
===References=== | ===References=== | ||
| − | # Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] | + | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] |
==Methotrexate monotherapy {{#subobject:d33308|Regimen=1}}== | ==Methotrexate monotherapy {{#subobject:d33308|Regimen=1}}== | ||
| Line 47: | Line 47: | ||
![[Levels_of_Evidence#Efficacy|Efficacy]] | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG)] | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ Osborne et al. 2011 (GOG 0174)] |
| − | |style="background-color:#1a9851"|Phase III | + | |style="background-color:#1a9851"|Phase III (C) |
|[[#Dactinomycin_monotherapy|Dactinomycin]] | |[[#Dactinomycin_monotherapy|Dactinomycin]] | ||
|style="background-color:#fc8d59"|Seems to have inferior CR rate | |style="background-color:#fc8d59"|Seems to have inferior CR rate | ||
| Line 58: | Line 58: | ||
'''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | '''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | ||
===References=== | ===References=== | ||
| − | # Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] | + | # '''GOG 0174:''' Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. [http://ascopubs.org/doi/full/10.1200/JCO.2010.30.4386 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068058/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21263100 PubMed] |
[[Category:Gestational trophoblastic neoplasia regimens]] | [[Category:Gestational trophoblastic neoplasia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gynecologic cancers]] | [[Category:Gynecologic cancers]] | ||
Revision as of 02:37, 10 August 2018
4 regimens on this page
6 variants on this page
|
Low-risk disease, all lines of therapy
Dactinomycin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Osborne et al. 2011 (GOG 0174) | Phase III (E) | Methotrexate | Seems to have superior CR rate |
Chemotherapy
- Dactinomycin (Cosmegen) 1.25 mg/m2 IV push once every 2 weeks
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed
Methotrexate monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Osborne et al. 2011 (GOG 0174) | Phase III (C) | Dactinomycin | Seems to have inferior CR rate |
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IM once per week
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- GOG 0174: Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed